The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Refractory asthma - beyond step 5, the role of new and emerging adjuvant therapies
Abstract
A small percentage of asthmatics have 'severe refractory asthma', where there is suboptimal response to currently available therapies. A number of novel therapies targeting key biological targets are becoming available. Asthma is a heterogeneous disease, and systematic evaluation of patients is important to target therapies to the underlying inflammatory subtype and clinical features. This review article outlines new and emerging treatments for severe asthma, including monoclonal antibodies targeting eosinophilic disease, anti-neutrophil strategies, novel bronchodilators and bronchial thermoplasty. We highlight the importance of individualized investigation, treatment and management of severe asthmatics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cytokines can also antagonize each other's effects.”
From Cytokine Research in Depression: Principles, Challenges, and Open Questions (2019) · cites this paper as [58]
In the citing paper
“As cytokine signaling often shows redundancy (53–55), synergy (47), antagonistic effects (56–59) or signaling cascades (60), it seems advisable to take all cytokines that work together or against each other into account and thus measure a whole range instead of a single cytokine.”
From Cytokine Research in Depression: Principles, Challenges, and Open Questions (2019) · cites this paper as [58]
Citations
Cites
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Moore, W. C., Meyers, D. A., Wenzel, S. E., Teague, W. G., Li, H., Li, X., D'Agostino, R., Castro, M., Curran-Everett, D., Fitzpatrick, A. M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0896oc · Cited by 2,129 · cited 1×
“There is no international consensus on how to divide asthma into these specific phenotypes, but recent work has focussed on ‘cluster analysis’, a method that groups people together with similar symptoms, signs and inflammatory features (Figure 2).(12,13) This method is useful to guide treatment according to how propor…”
MethodBritish Guideline on the Management of Asthma
British Thoracic Society Scottish Intercollegiate Guidelines Network (2008) · Thorax · doi:10.1136/thx.2008.097741 · Cited by 2,021
Cluster analysis and clinical asthma phenotypes
Haldar, P., Pavord, I. D., Shaw, D. E., Berry, M. A., Thomas, M., Brightling, C. E., Wardlaw, A. J., & Green, R. H. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200711-1754oc · Cited by 1,987 · cited 2×
“Clinical phenotypes of asthma identified by cluster analysis, adapted from Haldar et al.(12) Clusters are plotted and divided into three categories (red) based on how proportional symptoms are to airway inflammation.”
MethodMepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,871
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial
Green, R. H., Brightling, C. E., McKenna, S., Hargadon, B., Parker, D., Bradding, P., Wardlaw, A. J., & Pavord, I. D. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11679-5 · Cited by 1,755 · cited 1×
“A small proportion of patients with severe allergic asthma have persistently raised eosinophils levels in the sputum and blood, despite adequate treatment with corticosteroids after accounting for patient adherence to treatment.(43,44) IL-5, a cytokine that promotes eosinophil production and trafficking into the lungs…”
BackgroundLebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514 · cited 1×
“As per the anti-IL-5 antibody mepolizumab, this agent only demonstrated clinical effectiveness when the population was stratified for their eosinophilic pattern of airway inflammation.(55) Pitrakinra reduced allergen-induced late asthmatic responses and the need for rescue medication with minimal side effects.”
BackgroundMepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Nair, P., Pizzichini, M. M. M., Kjarsgaard, M., Inman, M. D., Efthimiadis, A., Pizzichini, E., Hargreave, F. E., & O'Byrne, P. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805435 · Cited by 1,356 · cited 1×
“Mepolizumab, a monoclonal antibody against IL-5, significantly reduced exacerbation rates and improved quality of life in patients with severe refractory eosinophilic asthma.(46,47) This was associated with a reduction in sputum and blood eosinophils but did not improve symptoms, forced expiratory volume in 1 second (…”
BackgroundRothenberg, M. E., & Hogan, S. P. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090720 · Cited by 1,356
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
WENZEL, S. E., SCHWARTZ, L. B., LANGMACK, E. L., HALLIDAY, J. L., TRUDEAU, J. B., GIBBS, R. L., & CHU, H. W. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.3.9812110 · Cited by 1,235 · cited 1×
“A small proportion of patients with severe allergic asthma have persistently raised eosinophils levels in the sputum and blood, despite adequate treatment with corticosteroids after accounting for patient adherence to treatment.(43,44) IL-5, a cytokine that promotes eosinophil production and trafficking into the lungs…”
Background(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.6.ats9-00 · Cited by 909
Evidence of a Role of Tumor Necrosis Factor α in Refractory Asthma
Berry, M. A., Hargadon, B., Shelley, M., Parker, D., Shaw, D. E., Green, R. H., Bradding, P., Brightling, C. E., Wardlaw, A. J., & Pavord, I. D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa050580 · Cited by 826
Reslizumab for Poorly Controlled, Eosinophilic Asthma: A Randomized, Placebo-controlled Study
Castro, M., Mathur, S., Hargreave, F., Boulet, L.-P., Xie, F., Young, J., Wilkins, H. J., Henkel, T., & Nair, P. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201103-0396oc · Cited by 716 · cited 1×
“Resilizumab, another anti-IL-5 monoclonal antibody, reduced sputum eosinophil levels and lung function with a non-significant trend towards reduced exacerbations in a placebo-controlled trial of poorly controlled asthmatics with eosinophilic inflammation.(48) Benralizumab is a novel agent that binds to the IL-5 recept…”
BackgroundCastro, M., Rubin, A. S., Laviolette, M., Fiterman, J., De Andrade Lima, M., Shah, P. L., Fiss, E., Olivenstein, R., Thomson, N. C., Niven, R. M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0354oc · Cited by 672 · cited 1×
“Clinical benefits witnessed in a sham-controlled trial included not only AQLQ improvement (primary endpoint) but also large improvement in exacerbation frequency, A&E attendances and hospital admissions, which, in open-label follow-up, persisted for up to five years.(19,65,66) In all the clinical trials published to d…”
BackgroundSelf-citationTiotropium in Asthma Poorly Controlled with Standard Combination Therapy
Kerstjens, H. A. M., Engel, M., Dahl, R., Paggiaro, P., Beck, E., Vandewalker, M., Sigmund, R., Seibold, W., Moroni-Zentgraf, P., & Bateman, E. D. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208606 · Cited by 669 · cited 2×
“Kerstjens et al.61 subsequently reported the results of two identical trials, showing a small bronchodilator effect and a 21% reduction in severe exacerbations in symptomatic asthmatics with persistent airflow obstruction when added to step 3/4 therapy.”
ResultBusse, W. W., Holgate, S., Kerwin, E., Chon, Y., Feng, J., Lin, J., & Lin, S.-L. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201212-2318oc · Cited by 666 · cited 1×
“A clinical trial has shown that Brodalumab, a human anti-IL-17 receptor monoclonal antibody, is safe in moderate to severe asthma, but, overall, no treatment effect was observed.(30) A possible improvement in asthma control was seen in a predefined subgroup with highly reversible airways disease warranting further stu…”
BackgroundChung, K. F., & Barnes, P. J. (1999) · Thorax · doi:10.1136/thx.54.9.825 · Cited by 638
Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis
Moore, W. C., Hastie, A. T., Li, X., Li, H., Busse, W. W., Jarjour, N. N., Wenzel, S. E., Peters, S. P., Meyers, D. A., & Bleecker, E. R. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.10.011 · Cited by 600 · cited 1×
“However, it is now clear that many asthmatics, particularly those with severe or non-allergic disease, do not have eosinophils in the airways.(9,10) There may be different reasons for this, for example, past steroid use, smoking or recurrent infection, but in a subgroup, it may be that the neutrophil is the primary in…”
BackgroundWenzel, S., Wilbraham, D., Fuller, R., Getz, E. B., & Longphre, M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61600-6 · Cited by 588 · cited 1×
“Pitrakinra reduced allergen-induced late asthmatic responses and the need for rescue medication with minimal side effects.(56) Dupilumab has recently been demonstrated to have an effect in preventing exacerbations and treatment failure in a novel study design when inhaled steroid treatment was actively withdrawn to in…”
BackgroundGlucocorticosteroids: current and future directions
Barnes, P. J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01199.x · Cited by 533 · cited 1×
“However, separating desired from undesired effects has been challenging for scientists.(70) A randomized controlled clinical trial of inhaled GW870086, a novel selective glucocorticoid, 74 Chronic Respiratory Disease 12(1)”
BackgroundHeterogeneity of Airway Inflammation in Persistent Asthma
Gibson, P. G., Simpson, J. L., & Saltos, N. (2001) · Chest · doi:10.1378/chest.119.5.1329 · Cited by 527
Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma
Peters, S. P., Kunselman, S. J., Icitovic, N., Moore, W. C., Pascual, R., Ameredes, B. T., Boushey, H. A., Calhoun, W. J., Castro, M., Cherniack, R. M., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008770 · Cited by 519
Howarth, P. H. (2005) · Thorax · doi:10.1136/thx.2005.045260 · Cited by 495
Clarithromycin Targets Neutrophilic Airway Inflammation in Refractory Asthma
Simpson, J. L., Powell, H., Boyle, M. J., Scott, R. J., & Gibson, P. G. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200707-1134oc · Cited by 482 · cited 1×
“A study in 45 severe refractory asthmatics showed that two months of treatment with clarithromycin 500 mg twice daily reduced airway neutrophils with improvement in AQLQ scores; the effect was greater in a subgroup of patients with non-eosinophilic asthma.(27) A recent randomized control trial of azithromycin as an ad…”
BackgroundBrusselle, G. G., VanderStichele, C., Jordens, P., Deman, R., Slabbynck, H., Ringoet, V., Verleden, G., Demedts, I. K., Verhamme, K., Delporte, A., et al. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202698 · Cited by 477 · cited 1×
“A recent randomized control trial of azithromycin as an add-on therapy for 6 months in exacerbation-prone severe asthma showed that the rate of severe exacerbations reduced in noneosinophilic asthma.(28) The recent ERS/ATS guidelines on severe asthma do not recommend the routine use of azithromycin for severe asthma.”
BackgroundA new perspective on concepts of asthma severity and control
Taylor, D. R., Bateman, E. D., Boulet, L.-P., Boushey, H. A., Busse, W. W., Casale, T. B., Chanez, P., Enright, P. L., Gibson, P. G., de Jongste, J. C., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00155307 · Cited by 472
Hastie, A. T., Moore, W. C., Meyers, D. A., Vestal, P. L., Li, H., Peters, S. P., & Bleecker, E. R. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.02.008 · Cited by 463 · cited 1×
“However, it is now clear that many asthmatics, particularly those with severe or non-allergic disease, do not have eosinophils in the airways.(9,10) There may be different reasons for this, for example, past steroid use, smoking or recurrent infection, but in a subgroup, it may be that the neutrophil is the primary in…”
BackgroundWenzel, S. E., Barnes, P. J., Bleecker, E. R., Bousquet, J., Busse, W., Dahlén, S.-E., Holgate, S. T., Meyers, D. A., Rabe, K. F., Antczak, A., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200809-1512oc · Cited by 460
Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease
Edwards, M. R., Bartlett, N. W., Clarke, D., Birrell, M., Belvisi, M., & Johnston, S. L. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.003 · Cited by 375
Denning, D. W., O'Driscoll, B. R., Powell, G., Chew, F., Atherton, G. T., Vyas, A., Miles, J., Morris, J., & Niven, R. M. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200805-737oc · Cited by 343 · cited 3×
“A more recent placebo-controlled trial of voriconazole did not match the findings with itraconazole.25 The duration of the voriconazole study may have been too short at 3 months, as the itraconazole study by Denning et al.24 demonstrated no response at two months, but clinically and statistically meaningful benefits a…”
BackgroundResultInfluentialSelf-citationNair, P., Gaga, M., Zervas, E., Alagha, K., Hargreave, F. E., O'Byrne, P. M., Stryszak, P., Gann, L., Sadeh, J., Chanez, P., et al. (2012) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2012.04014.x · Cited by 333 · cited 1×
“in asthma control and non-severe exacerbations.(29) Anti-IL-17 is important in promoting neutrophilic inflammation.”
BackgroundBronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma
Wechsler, M. E., Laviolette, M., Rubin, A. S., Fiterman, J., Lapa e Silva, J. R., Shah, P. L., Fiss, E., Olivenstein, R., Thomson, N. C., Niven, R. M., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.08.009 · Cited by 300 · cited 1×
“Clinical benefits witnessed in a sham-controlled trial included not only AQLQ improvement (primary endpoint) but also large improvement in exacerbation frequency, A&E attendances and hospital admissions, which, in open-label follow-up, persisted for up to five years.(19,65,66) In all the clinical trials published to d…”
BackgroundSelf-citationVenkayya, R., Lam, M., Willkom, M., Grünig, G., Corry, D. B., & Erle, D. J. (2002) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.26.2.4600 · Cited by 223 · cited 1×
“IL-4 and IL-13 are cytokines that drive allergic inflammation, and both share a common receptor.(50,51) IL-13 concentrations are increased in the airways of patients with asthma.”
BackgroundClinical review: severe asthma.
Papiris, S. A., Kotanidou, A. N., Malagari, K. S., & Roussos, C. (2002) · Critical Care · doi:10.1186/cc1451 · Cited by 213
Kew, K. M., Undela, K., Kotortsi, I., & Ferrara, G. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002997.pub4 · Cited by 208
Morjaria, J. B., Chauhan, A. J., Babu, K. S., Polosa, R., Davies, D. E., & Holgate, S. T. (2008) · Thorax · doi:10.1136/thx.2007.086314 · Cited by 190
Kellett, F., Redfern, J., & McL Niven, R. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2004.05.006 · Cited by 178
Self-citationDose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids
Noonan, M., Korenblat, P., Mosesova, S., Scheerens, H., Arron, J. R., Zheng, Y., Putnam, W. S., Parsey, M. V., Bohen, S. P., & Matthews, J. G. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.03.051 · Cited by 171 · cited 1×
“IL-13 monoclonal antibodies have shown a good safety profile in asthmatics.(53,54) A study of lebrikizumab in 219 poorly controlled asthmatics showed a significant improvement in FEV1, particularly in patients with high serum periostin levels (a biomarker of eosinophilic inflammation).”
BackgroundFranciosi, L. G., Diamant, Z., Banner, K. H., Zuiker, R., Morelli, N., Kamerling, I. M. C., de Kam, M. L., Burggraaf, J., Cohen, A. F., Cazzola, M., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70187-5 · Cited by 169 · cited 1×
“A new inhaled dual PD-3 and PD-4 inhibitor has undergone phase 1 trials, including in mild asthmatics, showing a good safety and efficacy profile.(67) There is a large body of work ongoing, identifying small molecules that are important in the transcription of inflammatory genes, such as p38 mitogen-activated protein…”
BackgroundEfficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial
Holgate, S. T., Noonan, M., Chanez, P., Busse, W., Dupont, L., Pavord, I., Hakulinen, A., Paolozzi, L., Wajdula, J., Zang, C., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00063510 · Cited by 168 · cited 1×
“However, whilst early small trials of therapy with anti-TNF-α in refractory asthma suggested possible benefits,(36,37) subsequent larger randomized controlled trials failed to show clear benefits whilst raising serious concerns regarding toxicity that have discouraged further study.(38,39)”
BackgroundInhaled p38α Mitogen-activated Protein Kinase Antisense Oligonucleotide Attenuates Asthma in Mice
Duan, W., Chan, J. H. P., McKay, K., Crosby, J. R., Choo, H. H., Leung, B. P. L., Karras, J. G., & Wong, W. S. F. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200408-1006oc · Cited by 163
Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis
Berry, M. A., Parker, D., Neale, N., Woodman, L. B., Morgan, A. J., Monk, P., Bradding, P. H., Wardlaw, A. J., Pavord, I. D., & Brightling, C. E. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.08.032 · Cited by 155 · cited 1×
“IL-13 concentrations are increased in the airways of patients with asthma.(52) Various approaches to inhibiting IL-13 and/or IL-4 have been developed:”
BackgroundBolanos, S. H., Khan, D. A., Hanczyc, M., Bauer, M. S., Dhanani, N., & Brown, E. S. (2004) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)61756-5 · Cited by 150 · cited 1×
“The change in body shape associated with OCS use can, in some, bring feelings of self-loathing and loss of self-worth and may, ultimately, lead to depression and isolation.(14) The prevalence of co-morbid conditions attributed to OCS increases with the frequency of use.”
BackgroundObesity-Associated Severe Asthma Represents a Distinct Clinical Phenotype
Gibeon, D. S., Batuwita, K., Osmond, M., Heaney, L. G., Brightling, C. E., Niven, R. M., Mansur, A. H., Chaudhuri, R., Bucknall, C. E., Rowe, A., et al. (2013) · CHEST Journal · doi:10.1378/chest.12-0872 · Cited by 140 · cited 1×
“For example, prevalence of GORD was 41% in the UK severe asthma population compared with 9% in the general population, and obesity (body mass index >28) was 40% in patients in the severe asthma registry study, but it is between 24% and 30% in the general population.(15) The comparative prevalence of other co-morbid co…”
BackgroundSelf-citationLuttmann, W., Knöchel, B., Foerster, M., Matthys, H., Virchow, J. C., Jr., & Kroegel, C. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.4.1678 · Cited by 131 · cited 1×
“IL-4 and IL-13 are cytokines that drive allergic inflammation, and both share a common receptor.(50,51) IL-13 concentrations are increased in the airways of patients with asthma.”
BackgroundWilkinson, M., Sugumar, K., Milan, S. J., Hart, A., Crockett, A. J., & Crossingham, I. R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001289.pub2 · Cited by 131
Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World Study
Barnes, N. C., Menzies-Gow, A. N., Mansur, A. H., Spencer, D. A., Percival, F., Radwan, A., & Niven, R. M. (2013) · Journal of Asthma · doi:10.3109/02770903.2013.790419 · Cited by 123 · cited 1×
“Recent real-life studies, both in the UK and internationally, have demonstrated that, in clinical practice, the observed benefits and response rates (approximately 70%) are higher than was experienced during clinical trials.(18) Bronchial thermoplasty has also recently received a licence for treatment.”
BackgroundSelf-citationRoflumilast with long-acting β2-agonists for COPD: influence of exacerbation history
Bateman, E. D., Rabe, K. F., Calverley, P. M. A., Goehring, U.-M., Brose, M., Bredenbröker, D., & Fabbri, L. M. (2011) · European Respiratory Journal · doi:10.1183/09031936.00178710 · Cited by 120
Safety of bronchial thermoplasty in patients with severe refractory asthma
Pavord, I. D., Thomson, N. C., Niven, R. M., Corris, P. A., Chung, K. F., Cox, G., Armstrong, B., Shargill, N. S., & Laviolette, M. (2013) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2013.05.002 · Cited by 104 · cited 1×
“Clinical benefits witnessed in a sham-controlled trial included not only AQLQ improvement (primary endpoint) but also large improvement in exacerbation frequency, A&E attendances and hospital admissions, which, in open-label follow-up, persisted for up to five years.(19,65,66) In all the clinical trials published to d…”
BackgroundSelf-citationRoflumilast attenuates allergen-induced inflammation in mild asthmatic subjects
Gauvreau, G. M., Boulet, L., Schmid-Wirlitsch, C., Côté, J., Duong, M. T., Killian, K. J., Milot, J., Deschesnes, F., Strinich, T. X., Watson, R. M., et al. (2011) · Respiratory Research · doi:10.1186/1465-9921-12-140 · Cited by 95
Efficacy and safety of roflumilast in the treatment of asthma
Bateman, E. D., Alonso, J. L. I., Harnest, U., Hofbauer, P., Magyar, P., Schmid-Wirlitsch, C., Leichtl, S., & Bredenbröker, D. (2006) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)61065-4 · Cited by 91 · cited 1×
“Roflumilast is a PDE-4 inhibitor that has been shown to have anti-inflammatory effects in asthma(40) and, subsequently, to improve lung function at high dose, at least, in mild to moderate asthmatics.(41) Its use has not yet been investigated in severe refractory asthma, but possible benefits in patients with COPD wit…”
BackgroundBateman, E. D., O’Byrne, P. M., Busse, W. W., Lötvall, J. O., Bleecker, E. R., Andersen, L., Jacques, L., Frith, L., Lim, J., & Woodcock, A. A. (2013) · Thorax · doi:10.1136/thoraxjnl-2013-203600 · Cited by 87 · cited 1×
“A recent clinical trial investigating the addition of vilanterol, a novel ultra-long-acting β-agonist, to ICS showed a reduction in risk of severe exacerbations and improved lung function in uncontrolled asthmatics compared with ICS alone.(63) A number of other bronchodilators are in development for both asthma and CO…”
BackgroundSingh, D., Kane, B., Molfino, N. A., Faggioni, R., Roskos, L. K., & Woodcock, A. A. (2010) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-10-3 · Cited by 84 · cited 1×
“IL-13 monoclonal antibodies have shown a good safety profile in asthmatics.(53,54) A study of lebrikizumab in 219 poorly controlled asthmatics showed a significant improvement in FEV1, particularly in patients with high serum periostin levels (a biomarker of eosinophilic inflammation).”
BackgroundSelf-citationSweeney, J., Brightling, C. E., Menzies-Gow, A. N., Niven, R. M., Patterson, C. C., Heaney, L. G., & on behalf of the British Thoracic Society Difficult Asthma Network (2012) · Thorax · doi:10.1136/thoraxjnl-2012-201869 · Cited by 81 · cited 6×
“UK severe asthma centres will still use these treatments if all other treatments have been exhausted and patients remain desperate to withdraw or reduce OCS.(4) Further research is needed on the benefits versus risks in severe asthma.”
BackgroundInfluentialSelf-citationUse of nebulised saline and nebulised terbutaline as an adjunct to chest physiotherapy.
Sutton, P. P., Gemmell, H. G., Innes, N. J., Davidson, J. M., Smith, F. W., LEGGE, J. S., & Friend, J. A. R. (1988) · Thorax · doi:10.1136/thx.43.1.57 · Cited by 80
Tiotropium in asthma: a systematic review
Colice, G., Befekadu, E., & Onofrei, C. D. (2014) · Journal of Asthma and Allergy · doi:10.2147/jaa.s38841 · Cited by 40 · cited 1×
“A recent systematic review concluded that tiotropium may have a beneficial role in moderate to severe asthma that remains uncontrolled despite ICS and long-acting beta-agonists; no safety concerns were raised.(62) A recent clinical trial investigating the addition of vilanterol, a novel ultra-long-acting β-agonist, to…”
BackgroundComet, R., Domingo, C., Larrosa, M., Morón, A., Rué, M., Amengual, M. J., & Marín, A. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2005.07.003 · Cited by 37 · cited 1×
“Small studies have suggested a modest steroidsparing benefit.(22,23) UK severe asthma centres will still use these treatments if all other treatments have been exhausted and patients remain desperate to withdraw or reduce OCS.”
BackgroundAn update on bronchodilators in Phase I and II clinical trials
Cazzola, M., Rogliani, P., Segreti, A., & Matera, M. G. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.710602 · Cited by 36 · cited 2×
“A recent systematic review concluded that tiotropium may have a beneficial role in moderate to severe asthma that remains uncontrolled despite ICS and long-acting beta-agonists; no safety concerns were raised.62 A recent clinical trial investigating the addition of vilanterol, a novel ultra-long-acting β-agonist, to I…”
BackgroundKanazawa, H. (2005) · Current Opinion in Pulmonary Medicine · doi:10.1097/01.mcp.0000198066.73328.3a · Cited by 32 · cited 1×
“Long-acting muscarinic antagonists have attracted attention as potential novel therapy in asthma, as they have several potentially beneficial effects that are complementary to standard inhaled therapy, such as bronchodilation, inhibition of mucus secretion and reduction in hyperinflation.(58) They have been shown to r…”
BackgroundBeneficial effect of inhaled mannitol and cough in asthmatics with mucociliary dysfunction
Daviskas, E., Anderson, S. D., Eberl, S., & Young, I. H. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.05.019 · Cited by 31 · cited 1×
“A very small clinical trial showed benefit from mannitol inhalation in mucocilliary clearance in asthmatics.(34) Bearing in mind the high prevalence of bronchiectasis observed in patients with severe asthma (33%; Menzies et al.”
BackgroundAsthma: the irreversible airways disease.
Carter, P. M., Heinly, T. L., Yates, S. W., & Lieberman, P. (1997) · PubMed · Cited by 23
NICE guidance on omalizumab for severe asthma
Diaz, R. A., Charles, Z., GEORGE, E. L., & Adler, A. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70066-3 · Cited by 15 · cited 1×
“sub-group of allergic patients who meet the National Institute for Clinical Excellence (NICE) guidelines criteria.(16) This is an example of a therapy that has emerged from research over the last 10 years to change the management for a small proportion (estimated between 10% and 15%)(17) of all patients with severe as…”
BackgroundBareille, P. J., Hardes, K., & Donald, A. (2013) · Journal of Asthma · doi:10.3109/02770903.2013.837480 · Cited by 14 · cited 1×
“in mild–moderate asthmatics disappointingly showed no effect on lung function or rescue medication use.(71)”
Background[Efficiency of methotrexate in the treatment of cortico-dependent asthmatic patients].
Domingo, C., Comet, R., García, M. B., Morón, A., & Montón, C. (1999) · PubMed · Cited by 8
Burton, A., Hargadon, B., Murphy, A., Brightling, C. E., Pavord, I. D., Wardlaw, A. J., Bradding, P. H., & Green, R. (2010) · Thorax · doi:10.1136/thx.2010.150961.20 · Cited by 3
Research works printed but not linked: 11
- Carter PM, 1997, J Investig Allergol Clin Immunol, 7, 566
- Domingo RC, 1999, Rev Clin Esp, 199, 142
- Agbetile J, 2013, J Allergy Clin Immunol, 10
- Richeldi L, 2005, Cochrane Database Syst Rev, CD002997
- Wilkinson M, 2014, Cochrane Database Syst Rev, 5, CD001289
- Gauvreau GM, 2011, Respir Res, 140, 12
- 10.1016/S0140-6736(02)11679-5 · DOI · Paper page
- Castro M, 2014, Am J Respir Crit Care Med, 101, A3699
- Singh D, 2010, BMC Pulm Med, 3, 10
- Novelli F, 2013, Monaldi Arch Chest Dis, 79, 109
- Befekadu E, 2014, J Asthma Allergy, 7, 11
Cited by
Cytokine Research in Depression: Principles, Challenges, and Open Questions
Himmerich, H., Patsalos, O., Lichtblau, N., Ibrahim, M. A. A., & Dalton, B. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00030 · Cited by 313
Skloot, G. S., Busse, P. J., Braman, S. S., Kovacs, E. J., Dixon, A. E., Fragoso, C. A. V., Scichilone, N., Prakash, Y. S., Pabelick, C. M., Mathur, S. K., et al. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201608-658st · Cited by 125
Severe asthma: anti-IgE or anti-IL-5?
Papathanassiou, E., Loukides, S., & Bakakos, P. (2016) · European Clinical Respiratory Journal · doi:10.3402/ecrj.v3.31813 · Cited by 36
Asthma Phenotypes and Endotypes: Implications for Personalised Therapy
Dean, K., & Niven, R. M. (2017) · BioDrugs · doi:10.1007/s40259-017-0242-5 · Cited by 24
Self-citationLi, X., Liu, T., Mo, X., Wang, R., Kong, X., Shao, R., McIntyre, R. S., So, K., & Lin, K. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.389360 · Cited by 21
“For example, IL-4 amplifies IL-3 to induce differentiation and activation of mast cells in a synergistic way, but also blocks the secretion of IL-12 (Del Prete, 1992; Georas et al., 2005; Kane et al., 2015).”
Background
Metadata
- Authors
- Kane, B., Fowler, S. J., & Niven, R.
- Affiliations
- Manchester Academic Health Science Centre (GB)
- Lancashire Teaching Hospitals NHS Foundation Trust (GB)
- Manchester Academic Health Science Centre, University Hospital of South Manchester, University of Manchester, Southmoor Road, Manchester, UK
- Corresponding author
- Kane, Binita
- ORCID
- Fowler, Stephen J
- Venue
- Chronic Respiratory Disease
- Publisher
- SAGE Publications
- Published
- 2014-12-09
- Volume
- 12
- Issue
- 1
- Pages
- 69-77
- ISSN
- 1479-9723 (ISSN-L)
- 1479-9731
- OpenAlex
- W2081294470
- Cited by
- 15
- References
- 65
- Citations by year
- 2024: 1 · 2023: 2 · 2022: 1 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 3 · 2015: 2
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Chronic Respiratory Disease (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Occupational exposure and asthma
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- refractory asthma, severe asthma, adjuvant therapy, monoclonal antibodies, eosinophilic asthma, bronchial thermoplasty, asthma phenotypes, personalized asthma management
- MeSH terms
- Omalizumab, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Antifungal Agents, Asthma, Bronchi, Bronchodilator Agents, Bronchoscopy, Fungi, Humans, Hypersensitivity, Hyperthermia, Induced, Tumor Necrosis Factor-alpha, Interleukin-4, Treatment Failure, Itraconazole, Anti-Asthmatic Agents, Macrolides, Phosphodiesterase 4 Inhibitors, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.